Abstract
Methimazole (MeimzH) is an anti-thyroid drug and the first choice for patients with Grave's disease. Two new copper(II) complexes of this drug: [Cu(MeimzH)(2)(NO(3))(2)]*0.5H(2)O and [Cu(MeimzH)(2)(H(2)O)(2)](NO(3))(2)*H(2)O were synthesized and characterized by elemental analysis, dissolution behavior, thermogravimetric analysis and UV-vis, diffuse reflectance, FTIR and EPR spectroscopies. As it is known that copper(II) cation can act as an inhibitor of alkaline phosphatase (ALP), the inhibitory effect of methimazole and its copper(II) complexes on ALP activity has also been investigated.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alkaline Phosphatase / antagonists & inhibitors*
-
Animals
-
Antithyroid Agents / chemical synthesis*
-
Antithyroid Agents / chemistry
-
Antithyroid Agents / metabolism*
-
Antithyroid Agents / therapeutic use*
-
Copper / chemistry*
-
Electron Spin Resonance Spectroscopy
-
Graves Disease / drug therapy*
-
Humans
-
Methimazole / chemical synthesis*
-
Methimazole / chemistry
-
Methimazole / metabolism*
-
Methimazole / therapeutic use*
-
Spectrophotometry, Ultraviolet
-
Spectroscopy, Fourier Transform Infrared
Substances
-
Antithyroid Agents
-
Methimazole
-
Copper
-
Alkaline Phosphatase